慢阻肺-哮喘重叠综合征经布地奈德/福莫特罗粉吸入剂结合孟鲁司特治疗的效果探析

Efficacy of Budesonide/Formoterol Powder Inhalation Combined with Montelukast in Treatment of COPD-asthma Overlap Syndrome

目的:研究在慢阻肺-哮喘重叠综合征患者的临床治疗中应用布地奈德/福莫特罗粉吸入剂结合孟鲁司特的临床效果。方法:选取2015年1月-2017年3月本院收治的慢阻肺-哮喘重叠综合征患者94例。按照治疗方法不同分为观察组和对照组,各47例。观察组患者接受布地奈德/福莫特罗粉吸入剂结合孟鲁司特治疗,对照组单一接受孟鲁司特治疗。比较两组治疗前后的CAT评分、肺功能(FEV_1、FEV_1%pred、FEV_1/FVC)、生活质量评分以及疗效。结果:观察组治疗后总有效率为95.74%,高于对照组的76.60%(P<0.05);治疗后1、3个月,观察组CAT评分为(12.38±4.93)、(9.18±2.03)分,均明显低于对照组的(15.42±3.86)、(11.45±1.86),比较差异均有统计学意义(P<0.05);治疗后1、3个月,观察组FEV_1/FVC分别为(55.54±2.36)%、(61.54±2.50)%,均高于对照组的(53.89±1.92)%、(57.43±3.27)%,比较差异均有统计学意义(P<0.05);治疗后,观察组生理、心理、环境、社会关系领域评分均明显高于对照组(P<0.05)。结论:慢阻肺-哮喘重叠综合征经布地奈德/福莫特罗粉吸入剂结合孟鲁司特治疗,可改善肺功能,同时能够更明显提升患者生活质量,可在临床推广。

To study the clinical effect of Budesonide/Formoterol Powder Inhalation combinedwith Montelukast in treatment of COPD-asthma overlap syndrome.Method:A total of94patients with COPDasthmaoverlap syndrome from January2015to March2017in our hospital were selected.According to differenttreatment methods,they were divided into observation group and control group,47cases in each group.The observation group received Budesonide/Formoterol Powder Inhalation combined with Montelukast,whilecontrol group received Montelukast alone.The CAT scores,pulmonary function(FEV1,FEV1%pred,FEV1/FVC),quality of life scores before and after treatment,and curative effects were compared between two groups.Result:The total effective rate of observation group was95.74%,which was higher than76.60%of controlgroup(P<0.05).After treatment1and3months,the CAT scores of observation group were(12.38±4.93)and(9.18±2.03)points,which were significantly lower than(15.42±3.86)and(11.45±1.86)points in control group,the differences were statistically significant(P<0.05).After treatment1and3months,the FEVl/FVC of observation group were(55.54±2.36)%and(61.54±2.50)%respectively,which were higher than(53.89±1.92)%and(57.43±3.27)%in control group,the differences were statistically significant(P<0.05).After treatment,the scores of physiology,psychology,environment and social relations in observation group were significantly higher than those of control group(P<0.05).Conclusion:COPD-asthma overlap syndrome treated with Budesonide/Formoterol Powder Inhalation combined with Montelukast can improve pulmonary function,at the same time can significantly improve the quality of life of patients,can be promoted in clinical practice.